| Literature DB >> 25318463 |
Min Lin1, Lin Zhao2, Wenlong Zhao1, Jing Weng1.
Abstract
Carotid atherosclerosis is a chronic inflammatory disease of the arterial wall. The present study aimed to identify changes in the gene expression and regulatory factors for atherosclerotic plaques of carotid atherosclerosis from an early to an advanced stage. The original data were downloaded from the NCBI GEO database under accession no. GSE28829. Differentially expressed genes (DEGs) were detected by the Robust Multiarray Average (RMA). The enriched Gene Ontology (GO) terms and pathways for DEGs using DAVID were subsequently identified. The transcriptional and microRNA (miRNA) regulatory network were constructed for the DEGs. Cis-regulatory signals were also investigated. More genes were activated in the advanced stage compared with the early stage. IGHG1 and SPP1 were upregulated, while MYBL1 and PLD were downregulated. The upregulated genes in the advanced stage were involved in atherosclerosis‑related GO terms such as immune, vascular and cell movement homeostasis. The DEGs were significantly enriched in cell adhesion molecules (CAMs) and the focal adhesion pathway. MMP9 and CFL2 played key roles in the transcriptional regulatory network. Moreover, miR-328 was identified as one of the hubs in the miRNA regulatory network. The results may therefore be used to determine the mechanism involved in carotid atherosclerosis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25318463 PMCID: PMC4214333 DOI: 10.3892/ijmm.2014.1960
Source DB: PubMed Journal: Int J Mol Med ISSN: 1107-3756 Impact factor: 4.101
Figure 1Hierarchical clustering analysis of 889 differentially expressed transcripts in all samples.
Figure 2The average expression value of 889 differentially expressed transcripts in each sample. Purple bars are the advanced samples and green bars are the early stage sample. Bar values are the standard error of the mean (SEM).
Figure 3The distribution of 889 differentially expressed transcripts (DETs) in the early and advanced stages. (A) The number of transcripts with a different FC. Blue shows the advanced stage samples, while yellow shows the early stage samples. (B) The fold change of DETs in the advanced samples when compared with its expression in the early stage samples with a different FC. FC represents the log2 fold change.
Major biological processes enriched by upregulated genes in early stage.
| Term | Count | P-value | FDR |
|---|---|---|---|
| GO:0007010: Cytoskeleton organization | 25 | 2.12E-07 | 3.51E-04 |
| GO:0007155: Cell adhesion | 29 | 1.14E-05 | 1.88E-02 |
| GO:0007517: Muscle organ development | 14 | 4.57E-05 | 7.56E-02 |
| GO:0006937: Regulation of muscle contraction | 7 | 1.16E-03 | 1.90E+00 |
| GO:0001558: Regulation of cell growth | 11 | 1.38E-03 | 2.25E+00 |
| GO:0044057: Regulation of system process | 14 | 1.80E-03 | 2.93E+00 |
| GO:0010959: Regulation of metal ion transport | 7 | 2.13E-03 | 3.46E+00 |
| GO:0007507: Heart development | 11 | 2.92E-03 | 4.73E+00 |
P≤0.05 and false discovery rate (FDR) ≤0.05.
Major biological processes enriched by upregulated genes in advanced stage.
| Term | Count | P-value | FDR |
|---|---|---|---|
| GO:0006955: Immune response | 86 | 4.85E-40 | 8.42E-37 |
| GO:0006952: Defense response | 65 | 1.40E-25 | 2.43E-22 |
| GO:0009611: Response to wounding | 57 | 1.10E-22 | 1.91E-19 |
| GO:0006954: Inflammatory response | 43 | 2.13E-20 | 3.69E-17 |
| GO:0006935: Chemotaxis | 27 | 2.20E-15 | 3.85E-12 |
| GO:0042330: Taxis | 27 | 2.20E-15 | 3.85E-12 |
| GO:0002252: Immune effector process | 21 | 2.08E-11 | 3.61E-08 |
| GO:0048584: Positive regulation of response to stimulus | 27 | 2.37E-11 | 4.11E-08 |
| GO:0007626: Locomotory behavior | 29 | 2.40E-11 | 4.16E-08 |
| GO:0002443: Leukocyte mediated immunity | 17 | 7.37E-11 | 1.28E-07 |
| GO:0002504: Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 12 | 8.24E-11 | 1.43E-07 |
| GO:0002250: Adaptive immune response | 16 | 1.47E-10 | 2.55E-07 |
| GO:0002253: Activation of immune response | 17 | 2.97E-10 | 5.16E-07 |
| GO:0002449: Lymphocyte mediated immunity | 15 | 4.22E-10 | 7.33E-07 |
| GO:0019882: Antigen processing and presentation | 16 | 4.49E-10 | 7.79E-07 |
| GO:0007610: Behavior | 33 | 2.54E-08 | 4.41E-05 |
| GO:0019724: B cell-mediated immunity | 12 | 3.99E-08 | 6.92E-05 |
| GO:0002478: Antigen processing and presentation of exogenous peptide antigen | 7 | 5.36E-08 | 9.29E-05 |
| GO:0007155: Cell adhesion | 40 | 1.72E-07 | 2.98E-04 |
| GO:0001568: Blood vessel development | 22 | 1.75E-07 | 3.04E-04 |
| GO:0002526: Acute inflammatory response | 14 | 3.02E-07 | 5.23E-04 |
| GO:0019884: Antigen processing and presentation of exogenous antigen | 7 | 3.29E-07 | 5.70E-04 |
| GO:0001775: Cell activation | 23 | 6.13E-07 | 1.06E-03 |
| GO:0030334: Regulation of cell migration | 17 | 1.43E-06 | 2.48E-03 |
| GO:0048514: Blood vessel morphogenesis | 19 | 1.45E-06 | 2.51E-03 |
| GO:0051270: Regulation of cell motion | 18 | 1.83E-06 | 3.18E-03 |
| GO:0055066: Di-, tri-valent inorganic cation homeostasis | 20 | 2.13E-06 | 3.69E-03 |
| GO:0045321: Leukocyte activation | 20 | 2.56E-06 | 4.44E-03 |
| GO:0006956: Complement activation | 9 | 3.78E-06 | 6.56E-03 |
| GO:0002541: Activation of plasma proteins involved in acute inflammatory response | 9 | 4.55E-06 | 7.90E-03 |
| GO:0001525: Angiogenesis | 15 | 6.60E-06 | 1.14E-02 |
| GO:0042592: Homeostatic process | 38 | 6.64E-06 | 1.15E-02 |
| GO:0040012: Regulation of locomotion | 17 | 7.55E-06 | 1.31E-02 |
| GO:0009617: Response to bacterium | 17 | 8.07E-06 | 1.40E-02 |
| GO:0055080: Cation homeostasis | 21 | 8.17E-06 | 1.42E-02 |
| GO:0050865: Regulation of cell activation | 16 | 1.04E-05 | 1.80E-02 |
| GO:0048878: Chemical homeostasis | 29 | 1.48E-05 | 2.57E-02 |
| GO:0006874: Cellular calcium ion homeostasis | 16 | 1.77E-05 | 3.07E-02 |
P≤0.05 and false discovery rate (FDR) ≤0.05.
Enriched pathways of differentially expressed transcripts.
| Term | Count | P-value | FDR |
|---|---|---|---|
| hsa05322: Systemic lupus erythematosus | 21 | 3.65E-08 | 0.00004 |
| hsa04514: Cell adhesion molecules (CAMs) | 23 | 2.78E-07 | 0.00033 |
| hsa04612: Antigen processing and presentation | 18 | 3.26E-07 | 0.00039 |
| hsa04610: Complement and coagulation cascades | 16 | 7.32E-07 | 0.00087 |
| hsa05310: Asthma | 10 | 5.73E-06 | 0.00681 |
| hsa05416: Viral myocarditis | 15 | 5.92E-06 | 0.00704 |
| hsa04142: Lysosome | 19 | 1.13E-05 | 0.01347 |
| hsa04672: Intestinal immune network for IgA production | 12 | 1.66E-05 | 0.01978 |
P-value ≤0.05 and false discovery rate (FDR) ≤0.05.
Figure 4The core transcriptional regulatory network of upregulated genes (RMA log2 transformed values >2). Green nodes are the target genes, and the other nodes are the transcription factors. Arrows show that transcription factors target the genes.
Figure 5The core transcriptional regulatory network of downregulated genes (RMA log2 transformed values <-1). Green nodes are the target genes, and the other nodes are the transcription factors. Arrows show that transcription factors target the genes.
Figure 6Significantly enriched TF motifs by DETs. Enriched motifs of (A) upregulated and (B) downregulated genes.
Figure 7The core miRNA regulatory network of upregulated genes (RMA log2 transformed values >2) in advanced stage samples.
Figure 8The core miRNA regulatory network of upregulated genes (RMA log2 transformed values >2) in the early stage samples.